KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $14.9 million.

  • NovoCure's Free Cash Flow rose 495960.91% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.2 million, marking a year-over-year increase of 1667.05%. This contributed to the annual value of -$69.2 million for FY2024, which is 3107.17% up from last year.
  • As of Q3 2025, NovoCure's Free Cash Flow stood at $14.9 million, which was up 495960.91% from -$21.4 million recorded in Q2 2025.
  • NovoCure's 5-year Free Cash Flow high stood at $23.6 million for Q2 2021, and its period low was -$46.3 million during Q1 2025.
  • For the 5-year period, NovoCure's Free Cash Flow averaged around -$8.1 million, with its median value being -$10.1 million (2022).
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 789846.15% in 2022, then skyrocketed by 495960.91% in 2025.
  • NovoCure's Free Cash Flow (Quarter) stood at $130000.0 in 2021, then tumbled by 7898.46% to -$10.1 million in 2022, then tumbled by 110.88% to -$21.4 million in 2023, then soared by 42.03% to -$12.4 million in 2024, then surged by 220.38% to $14.9 million in 2025.
  • Its last three reported values are $14.9 million in Q3 2025, -$21.4 million for Q2 2025, and -$46.3 million during Q1 2025.